Loading stock data…
ZURA
$3.69+0.16 (+4.53%)
After Hours$3.69+0.00 (+0.00%)· Last close Jun 9
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Zura Bio Limited in the Healthcare sector is trading at $3.69 with a market capitalization of $366M. Wall Street consensus targets $15.67 (6 analysts), implying a +324.6% move over the next 12 months. The stock is currently 50% below its 52-week high of $7.44, remaining 19.4% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +324.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$3.69
Potential Downside
0%
Whystock Fair Value$3.69
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Mean target$15.67+324.6%
Range$11.00 – $26.00
Fundamentals
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody enginee...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$366.24M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-34.78%
Volume
Today's trading volume
575,983
Recent News
Here's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
One Zura Bio Insider Raised Their Stake In The Previous Year
Viewing insider transactions for Zura Bio Limited's ( NASDAQ:ZURA ) over the last year, we see that insiders were net...
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million
This biotech specializes in monoclonal antibody therapies for inflammatory and immunological diseases with significant unmet needs.
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges
RAPT Therapeutics develops oral therapies for oncology and inflammatory diseases, with lead candidates progressing in clinical trials.
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst
This clinical-stage biotech develops therapies targeting hematologic disorders, with a pipeline centered on red blood cell biology.